Par Pharmaceutical Begins Shipment of Generic Buprenex® (CIII)
Company Introduces First Generic Version of the Brand
Chestnut Ridge, NY, Aug. 4, 2015 - Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for buprenorphine hydrochloride (HCl) injection (CIII), EQ 0.3 mg base/mL. Buprenorphine HCl is the generic version of Indivior's Buprenex® (CIII) and is indicated for the relief of moderate to severe pain.
Par has begun shipping buprenorphine HCl injection (CIII), EQ 0.3 mg base/mL, which is packaged in cartons of five 1 mL single-dose vials. According to IMS Health data, annual U.S. sales of Buprenex® (CIII) and its generic equivalent are approximately $14 million.
Important Information About Buprenorphine HCl for Injection (CIII)
Buprenorphine hydrochloride injection should not be administered to patients who have been shown to be hypersensitive to the drug. Refer to full prescribing information for Warnings and Precautions at www.parpharm.com.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.
Return to News Releases ›